This white paper describes why LC or LC-MS/MS methods must be carefully evaluated as they are adopted for LC+AMS use and why the resultant LC+AMS method must be fully validated before use. A three-batch validation is the only way to ensure method reproducibility and deliver LC+AMS data reliably.
Presented at the 21st Workshop on the Synthesis and Applications of Isotopes and Isotopically Labelled Compounds, International Isotope Society-Central European Division, Bad Soden, Germany
Download the presentation from here
Successful Clinical [14C] Microtracer Investigations – Case Studies from GSK and Genentech
Thursday, 24th September 2015 at 11:00 am EDT – 12:00 pm EDT
Go here to pre-register for the webinar
Stephen English – “The successful application of carbon isotopes in preclinical and clinical pharmaceutical research”
Friday, 2nd October 2015
International Isotope Society-Central European Division
21st Workshop on the Synthesis and Applications of Isotopes and Isotopically Labelled Compounds
Bad Soden, Germany
Surveying the Boundaries of Accelerator Mass Spectrometry: The Widening Scope of an Evolving Technology
Read the presentation
Go here to download speaker presentations, listen to and watch a recording of the presentations or read our comprehensive Q&A
Our concise two-pager was written by our AMS engineer Eric Guarin
Download How AMS Detection Works
Successful clinical 14C microtracer investigations: What can contemporary AMS do for you?
Expertise enables new AMS applications, Xceleron grows analytical operations
(Germantown, MD, USA; January 26, 2015) –Xceleron, a leader in the use of microtracers and Accelerator Mass Spectrometry (AMS) in novel life sciences investigations, has announced that it is retaining the consulting services of Graham Lappin (Visiting Professor of Pharmacology at the University of Lincoln, UK). Professor Lappin will advise the company and its customers on the application of microtracers in drug target research, clinical development and new non-pharmaceutical applications.
Professor Lappin has a long history and deep connections with the company going back to its early days. He also played an important role during Xceleron’s growth from a research-oriented laboratory in the UK to present-day in the US where it develops robust fit-for-purpose analytical methodology associated with AMS.
“Our relationship with Graham is important at this time for Xceleron” said Dr Michael Butler, CEO of Xceleron. “We have established a reputation for delivering representative, accurate and precise analytical data using AMS detection. This has been achieved by hiring accomplished analytical chemists who can develop and validate robust analytical methods around AMS. We are now turning the company’s full-time resources to scaling-up that service. Graham will help us customize our approach to novel cost-efficient clinical investigations and to continue applying our analytical expertise in new areas of drug research and non-pharmaceutical product development”
A guide to transferring and validating quantitative analytical methods for LC+AMS
"...AMS [is] an invaluable tool in our early drug development program, allowing us to quickly assess bioavailability in humans and focus resources on our most promising drug candidates going forward."
Find out how we can help you accelerate your drug-development program.